T hrombi are fibrin-laced platelet plugs, which maintain the vascular integrity after endothelial damage. Loss of endothelial integrity exposes the platelets in the blood to prothrombotic substrates in the vascular wall and causes platelet activation. The activated platelets express surface molecules including glycoprotein IIb/IIIa and P-selectin, which allow aggregation of platelets into a plug, and secrete substances to activate and attract other platelets. Endothelial damage also activates coagulation cascades, leading to the formation of thrombin. Thrombin converts fibrinogen into fibrin strands, which are cross-linked by factor XIII (FXIIIa), resulting in the formation of the fibrin network bracing the platelet plug. In addition, thrombin causes further platelet activation. Inappropriate or excessive formation of thrombus is the cause of pulmonary emboli, deep venous thrombosis, myocardial infarction, and cerebral stroke. Besides endothelial damage, stasis of blood and procoagulative state of the blood can cause or contribute to thrombus formation in the pathological settings.
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In this issue of Circulation: Cardiovascular Imaging, Ay et al 1 describe in vivo detection of thrombi by positron emission tomographic imaging using 64 Cu-fibrin-binding probe 7 (FBP7), a small fibrin-targeted cyclic peptide. The authors report high target-to-background ratio of the tracer uptake in rats with carotid crush injury-induced mural thrombosis and in rats after intracarotid thrombus placement. Moreover, the tracer allowed in vivo monitoring of thrombus dissolution over time after recombinant tissue-type plasminogen activator treatment. The authors claim that a clinically applicable molecular imaging technique to visualize thrombi components may be a valuable tool. First, whole body imaging with such a probe could be applied for more sensitive and precise thrombus detection. This would be particularly useful in the situations where thrombus diagnosis is difficult, such as in cases of chest pain or stroke of unknown origin, suspected endocarditis, or intracardiac thrombus. Second, molecular imaging may offer clinically relevant information on the composition of thrombi. As illustrated by the authors, measurement of thrombus fibrin content may allow prediction of effect of fibrin-targeted thrombolytic therapy. Last, molecular imaging techniques may comprise a useful research tool for preclinical and clinical studies on the temporal development of plaque components.
Worthy Targets for Thrombus Imaging
For molecular imaging of thrombi, various key players in the coagulation cascade including thrombin, fibrin, and FXIIIa, and for detection of activated platelets, glycoprotein IIb/IIIa and P-selectin have been exploited as targets. Most experience has been obtained with fibrin imaging. Proof of principle of clinical thrombus imaging using fibrin-targeted single-photon emission computed tomography (SPECT) tracers was reported ≈30 years ago. 2, 3 Since then, various approaches have been evaluated to target fibrin including computed tomography 4 and near infrared fluorescence 5 and SPECT 2,3,6-9 probes. Initial tracers developed were based on tissue-type plasminogen activator, but these have not been pursued into clinical studies. More recently, feasibility of SPECT imaging using fibrin-targeted peptides similar to FBP7 has been reported. 10, 11 Although production of the SPECT tracers may be more widely available and cheaper, the PET imaging with FBP7 benefits from the superior sensitivity and spatial resolution compared with the SPECT tracers.
Substantial experience has been obtained with molecular MRI using the gadolinium-based nanoparticle EP-2104R. Feasibility of thrombus detection with this nanoparticle has been demonstrated in >5 different animal models of arterial and venous thrombosis. [12] [13] [14] [15] [16] [17] Also, clinical feasibility of thrombus imaging was recently shown in a small group of patients with thrombus in the left ventricle, left or right atrium, thoracic aorta, or carotid artery. 18 Similar to the present study, EP-2104R MRI was successfully used to predict the effect of tissue-type plasminogen activator in mice with inferior vena cava thrombi. 12 When compared with 64 Cu-FBP7, EP-2104R benefits from the high spatial resolution and lack of radiation burden associated with MRI. However, the use of EP-2104R requires a prescan and postscan, which could become a limitation in acute clinical situations. Finally, 64 Cu-FBP7 positron emission tomography is a more sensitive imaging method than EP-2104R MRI, even at substantially lower administered doses. This is especially relevant for detecting the older thrombi with lower fibrin content. 12 Besides fibrin, FXIIIa [19] [20] [21] [22] [23] [24] [25] and thrombin 26, 27 have been evaluated as targets for thrombus imaging in the preclinical studies ( Figure) . Thrombin and FXIIIa are important factors in the coagulation cascade, and probes targeting these molecules promise to be excellent research tools for elucidation of the temporal roles of these factors in vivo. However, because these molecules play a role in the formation of the thrombus and are not incorporated into the thrombus, one may speculate that these probes will be less sensitive for detection of older July 2014 thrombi than fibrin-targeted probes. Because they could also be used to predict effect of standard thrombolytic treatment, fibrin-targeted agents may also be more attractive probes for clinical translation.
Finally, various studies have also focused on detection of activated platelets. Ultrasound 28-32 SPECT 33-38 and MRI 39, 40 probes specific for glycoprotein IIb/IIIa and a SPECT 41 and an MRI 42 probe specific for P-selectin have been evaluated. Although the studies evaluating probes targeted at P-selectin showed promising results, it is not specific for activated platelets. P-selectin is abundantly expressed on activated endothelial cells, and an intense uptake of 99m Tc-Fucoidan has been observed not only in thrombi but also bound to activated endothelium in a rat model of ischemia and reperfusion. 41 Therefore, because of the higher specificity, glycoprotein IIb/ IIIa seems to be a more attractive target.
It remains to be seen whether activated platelets are or fibrin is the optimal target for the molecular imaging of thrombus. If the sensitivity of fibrin-targeted probes proves too low to clinically detect older thrombi with lower fibrin content, platelet imaging may prove to be superior. However, if fibrin targeting is sensitive enough even to detect the older plaques, its advantage of predicting effect of thrombolytic therapy may become decisive.
Molecular Imaging Clarifies Pathogenesis
Molecular imaging is a unique strategy that is able to target key steps in cellular or subcellular biological processes in a living organism and offers a distinct potential to detect disease in subclinical and early stages. 43 In addition to addressing the diagnostic query, molecular targeting helps clarify pathogenetic mechanisms. 43 Newer understanding may allow better targeting. Therefore, the pathophysiology of a disease process and development of targeted imaging are interdependent and complementary. The more we know of the disease the better AA indicates abdominal aorta; AAA, abdominal aorta aneurysm; ApoE, apolipoprotein E; CT, computed tomography; DVT, deep venous thrombosis; FXIII, factor XIII; GP, glycoprotein; ICA, internal carotid artery; IVC, inferior vena cava; LAD, left anterior descending coronary artery; LDLR, low-density lipoprotein receptor; MCA, middle cerebral artery; NIRF, near infrared fluorescence; and SPECT, single-photon emission computed tomography. we image, and the better we image the more we understand the disease process. Review of the historical evolution of any molecular imaging test should substantiate our claim. 44 Identification of the worthy targets, which are abundantly expressed in the diseased tissue provide a high target-to-background contrast for hot spot imaging. Alternatively, identification of moieties, which are conspicuously absent from the target tissue, allows a cold-spot pattern. 44 Once a target and targeting agent are identified, the imaging can be performed by conjugation of the imaging probe with appropriate reporter; molecular imaging is not limited by imaging modality.
The National Cancer Institute has identified molecular imaging as 1 of the 6 most rewarding opportunities for development, 45 and a major thrust has been placed on molecular imaging in the National Institute of Biomedical Imaging and Biomedical Engineering. At the National Heart, Lung, and Blood Institute also, the field of cardiovascular molecular imaging has surely progressed. The Imaging Probe Development Center was initiated in the incubator space of the Common Fund and has transitioned to the National Heart, Lung, and Blood Institute intramural program. 46 It is dedicated to the production of new imaging probes for the intramural National Institutes of Health research community. In the blueprint for the next decade, National Heart, Lung, and Blood Institute created a living, working plan, and identified 3 strategic priorities: (1) improve understanding of the molecular and physiological basis of health and disease for improved approach to prevention, diagnosis, and treatment (form-to-function), (2) to develop personalized preventive and therapeutic regimens for cardiovascular, lung, and blood diseases (function-to-cause), and (3) generate an improved understanding of the processes involved in translating research into practice to improve public health and stimulate scientific discovery (cause-to-cures). 47 Within the purview of the first goal, biomarkers would be discovered that differentiate clinically relevant disease subtypes and that identify new molecular targets for application to prevention, diagnosis (including imaging), and therapy. The latter would attempt to identify molecular signatures that allow complex disease phenotypes to be stratified into clinically relevant categories and to develop in vivo molecular imaging methods and probes for investigating the biology of disease processes.
In this context, development of novel molecular imaging strategies for detection of thrombi should help elucidate the pathology of thrombus formation. It might determine the (temporal) role of individual players in thrombus formation. For instance, using A15 NIRF imaging, Jaffer and colleagues showed the highest FXIII activity during the first 24 hours of thrombus formation. Andia et al 12 used EP-2104R MRI to demonstrate that the fibrin content of thrombus increased during the first 7 days and then reduced gradually over time. Furthermore, microemboli and microthrombi that are implicated in (silent) brain injury have been identified in the mice after thrombus placement in carotid artery. 19 The total (targeted) uptake in the brain correlated with the brain injury. Similarly, coronary microthrombi have been visualized using CREKA, a fibrin-targeted MRI/NIRF probe. 48 The feasibility of predicting 1, 12 and monitoring the efficacy of therapy in thromboembolic disorders has been widely reported. 1, 12, 24, 32 An overview of the thrombus-targeted molecular imaging is provided in the Table.
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